ReviewBBA advances2025
"Netrin-slaying nanoparticles: A new frontier in cancer therapy".
Review in BBA advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Netrin-1, a secreted laminin-related protein, was first characterized for its pivotal role in guiding axonal growth during nervous system development. However, recent research has revealed its involvement in cancer progression and metastasis. Understanding the signaling pathways through which Netrin-1 operates in cancer is crucial for elucidating its mechanisms and exploring therapeutic interventions. Netrin-1 protein controls the biological processes of cancer cells, guiding axon pathfinding and transmitting signals that are essential for migration, differentiation and cell survival via UNC5 and DCC-family receptors. To elaborate further, Netrin1 controls YAP signalling through its neogenin receptor, which affects the EMT process in gastric cancer. Researchers have also utilized the Netrin-1 protein with different nanoparticles to explore its way to prevent cancer progression. Moreover, Researchers evaluated the use of nanoparticles as an immunosensor, therapeutic and imaging tools targetting the Netrin-1 protein, which open several ways to combat cancer. This review explores how Netrin-1 influences the AKT signaling cascade impacting hippo signaling, YAP pathways and EMT process with DCC receptor. It also discusses the involvement of UNC5B and Netrin-1 in regulating ERK/MAPK signaling pathways and induction of apoptosis when Netrin-1 is absent. Moreover, it underscores the therapeutic potential of UNC5B-induced cell cycle arrest in specific cancer. Also, it delves into the diverse forms of netrin and its potential role in cancer and the glims of nanoparticles use with it. Underlining the necessity for more research to comprehend their functions in signaling cascades using the nanomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.